Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.38 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.37 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.37 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6831054 | 1.00 | POLB (0.45) | POLBTSHRNPSR1DPP4EPHX2 | |
| SCHEMBL6830216 | 1.00 | POLB (0.45) | POLBTSHRNPSR1DPP4EPHX2 | |
| SCHEMBL6830489 | 0.97 | POLB (0.44) | POLBTSHRNPSR1DPP4EPHX2 | |
| SCHEMBL6827578 | 0.97 | POLB (0.44) | POLBTSHRNPSR1DPP4EPHX2 | |
| SCHEMBL6829975 | 0.97 | POLB (0.44) | POLBTSHRNPSR1DPP4EPHX2 | |
| SCHEMBL6830137 | 0.89 | POLB (0.42) | POLBTSHRNPSR1DPP4KMT2A | |
| SCHEMBL6830930 | 0.86 | POLB (0.41) | POLBTSHRNPSR1DPP4KMT2A | |
| SCHEMBL6830939 | 0.82 | HDAC8 (0.37) | EPHX2CYP3A4GNAI3GNAO1GNAI1 | |
| SCHEMBL6830913 | 0.82 | HDAC8 (0.37) | EPHX2CYP3A4GNAI3GNAO1GNAI1 | |
| SCHEMBL6830054 | 0.82 | HDAC8 (0.37) | EPHX2CYP3A4GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6770656-B2 | NEURODEGENERATIVE DISORDERS; ANTIEPILEPTIC AND ANTIISCHEMIC AGENTS; INFERTILITY, CARDIOVASCULAR DISORDERS, RENAL HYPOXIA, HEPATITIS AND AIDS TREATMENT | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2004-08-03 | — | — | US | claimed |
| US-20030216427-A1 | Amine derivatives for the treatment of apoptosis | MERCK SERONO SA (CH) | 2003-11-20 | — | — | US | claimed |
| EP-1125925-A1 | Amine derivatives for the treatment of apoptosis | Applied Research Systems ARS Holding N.V. (AN) | 2001-08-22 | — | — | EP | claimed |
| US-6770656-B2 | NEURODEGENERATIVE DISORDERS; ANTIEPILEPTIC AND ANTIISCHEMIC AGENTS; INFERTILITY, CARDIOVASCULAR DISORDERS, RENAL HYPOXIA, HEPATITIS AND AIDS TREATMENT | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2004-08-03 | — | — | US | disclosed |
| US-20030216427-A1 | Amine derivatives for the treatment of apoptosis | MERCK SERONO SA (CH) | 2003-11-20 | — | — | US | disclosed |
| EP-1125925-A1 | Amine derivatives for the treatment of apoptosis | Applied Research Systems ARS Holding N.V. (AN) | 2001-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216427-A1 | Amine derivatives for the treatment of apoptosis | BAD, BAX, BCL2 | POLB 1144/4885TSHR 3662/4885NPSR1 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.